文献速递精神分裂症与精神病性障碍

EMPOWER混合数字干预预防精神分裂症复发的可行性集群随机试验

The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia.
PubMed 文献 · Lancet Psychiatry · 2022-01-01

该多中心可行性集群随机对照试验在格拉斯哥和墨尔本社区精神卫生服务中心比较EMPOWER混合数字干预(智能手机监测早期预警信号+同伴支持+临床分诊)与常规照护,共随机化73名近2年内有复发的精神分裂症谱系服务使用者。

要点

  • EMPOWER组71%参与者达到每日监测依从性>33%的预设可行性标准。
  • EMPOWER组29例不良事件 vs 常规照护组25例,其中13例为app相关不良事件。

核心结论

  • 数字技术监测早期预警信号联合同伴支持与临床分诊以检测和预防复发的试验似乎可行、安全且可接受,值得进一步开展主试验。

研究设计与样本

  • 多中心可行性集群随机对照试验,在格拉斯哥和墨尔本的社区精神卫生服务中心开展,以CMHS为随机化单位。
  • 共识别并随机化8个CMHS(格拉斯哥6个、墨尔本2个),包含47名 care coordinator。
  • 2018年1月19日至8月8日招募86名服务使用者,73名被随机化(EMPOWER组42名[58%],常规照护组31名[42%])。
  • 参与者年龄>16岁、经病例记录确认精神分裂症或相关诊断、能提供知情同意、与CMHS有接触、且既往2年内有复发。
  • 主要终点为12个月,主要结局为可行性、可接受性、可用性和安全性,通过面对面访谈评估。

主要发现

  • 12个月时主要结局收集到EMPOWER组32名(76%)和常规照护组30名(97%)服务使用者。
  • EMPOWER组29例不良事件 vs 常规照护组25例不良事件。
  • app相关不良事件13例,影响11人,其中1例为严重不良事件。

关键数值与推荐

  • 可行性标准为每日监测依从性>33%,EMPOWER组30名(71%)达到该标准。
  • 不良事件:EMPOWER组29例 vs 常规照护组25例;app相关不良事件13例,影响11人,其中1例严重。

临床怎么用

  • EMPOWER将智能手机主动监测早期预警信号与同伴支持促进自我管理、临床分诊促进获得复发预防相结合。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early warning signs monitoring by service users with schizophrenia has shown promise in preventing relapse but the quality of evidence is low. We aimed to establish the feasibility of undertaking a definitive randomised controlled trial to determine the effectiveness of a blended digital intervention for relapse prevention in schizophrenia. METHODS: This multicentre, feasibility, cluster randomised controlled trial aimed to compare Early signs Monitoring to Prevent relapse in psychosis and prOmote Well-being, Engagement, and Recovery (EMPOWER) with treatment as usual in community mental health services (CMHS) in Glasgow and Melbourne. CMHS were the unit of randomisation, selected on the basis of those that probably had five or more care coordinators willing to participate. Participants were eligible if they were older than 16 years, had a schizophrenia or related diagnosis confirmed via case records, were able to provide informed consent, had contact with CMHS, and had had a relapse within the previous 2 years. Participants were randomised within stratified clusters to EMPOWER or to continue their usual approach to care. EMPOWER blended a smartphone for active monitoring of early warning signs with peer support to promote self-management and clinical triage to promote access to relapse prevention. Main outcomes were feasibility, acceptability, usability, and safety, which was assessed through face-to-face interviews. App usage was assessed via the smartphone and self-report. Primary end point was 12 months. Participants, research assistants and other team members involved in delivering the intervention were not masked to treatment conditions. Assessment of relapse was done by an independent adjudication panel masked to randomisation group. The study is registered at ISRCTN (99559262). FINDINGS: We identified and randomised eight CMHS (six in Glasgow and two in Melbourne) comprising 47 care coordinators. We recruited 86 service users between Jan 19 and Aug 8, 2018; 73 were randomised (42 [58%] to EMPOWER and 31 [42%] to treatment as usual). There were 37 (51%) men and 36 (49%) women. At 12 months, main outcomes were collected for 32 (76%) of service users in the EMPOWER group and 30 (97%) of service users in the treatment as usual group. Of those randomised to EMPOWER, 30 (71%) met our a priori criterion of more than 33% adherence to daily monitoring that assumed feasibility. Median time to discontinuation of these participants was 31·5 weeks (SD 14·5). There were 29 adverse events in the EMPOWER group and 25 adverse events in the treatment as usual group. There were 13 app-related adverse events, affecting 11 people, one of which was serious. Fear of relapse was lower in the EMPOWER group than in the treatment as usual group at 12 months (mean difference -7·53 (95% CI -14·45 to 0·60; Cohen's d -0·53). INTERPRETATION: A trial of digital technology to monitor early warning signs blended with peer support and clinical triage to detect and prevent relapse appears to be feasible, safe, and acceptable. A further main trial is merited. FUNDING: UK National Institute for Health Research Health Technology Assessment programme and the Australian National Health and Medical Research Council.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gumley AI, Bradstreet S, Ainsworth J, et al. The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. Lancet Psychiatry. 2022. PMID: 35569503. doi:10.1016/S2215-0366(22)00103-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。